Zolpidem
Zolpidem (Ambien) is a prescription sleep medication; it can cause dependence, complex sleep behaviors like sleep-driving, and is dangerous combined with alcohol or other depressants.
Overview
Zolpidem, sold under the brand name Ambien, is a prescription sedative-hypnotic used for short-term treatment of insomnia. It is often called a 'Z-drug' — it is not a benzodiazepine chemically, but it acts on the same brain system and shares many of the same risks. It is intended for short-term use because tolerance and dependence can develop, and it is known for an unusual and serious effect: complex sleep behaviors such as sleep-walking, sleep-eating, and even sleep-driving, performed with no memory of them afterward. Like other CNS depressants, it is dangerous in combination with alcohol or other sedatives. It is widely prescribed and also misused.
Source: MedlinePlus; FDA; PubChem CID 5732
Chemistry & mechanism of action
Zolpidem acts on the same GABA-A receptor system as benzodiazepines, enhancing the calming effect of the neurotransmitter GABA to slow brain activity and promote sleep, though it binds somewhat more selectively to the receptor subtypes associated with sedation. Because it works through this same inhibitory system, it carries the class risk of dangerous CNS and breathing suppression when combined with other depressants. The drug is relatively short-acting, designed to help with sleep onset, but its effects on the brain during partial wakefulness are thought to underlie the complex sleep behaviors it can cause. Repeated use can lead to tolerance and dependence.
Source: MedlinePlus; PubChem CID 5732
Effects
Zolpidem produces drowsiness and sleep, and common effects include grogginess, dizziness, and impaired coordination, sometimes lingering into the next morning and impairing driving. The drug's hallmark adverse effect is complex sleep behavior — walking, eating, making phone calls, having conversations, or driving while not fully awake, with no memory of it — which can be dangerous and has prompted strong regulatory warnings. Some people experience memory gaps, confusion, or unusual behavior. With repeated use, tolerance and dependence can develop, and stopping after regular use can cause rebound insomnia and withdrawal. Effects are intensified by alcohol and other sedatives.
Source: MedlinePlus; FDA
Risks & harms
Two specific dangers stand out. First, complex sleep behaviors: zolpidem can cause people to carry out activities — including driving — while not fully awake and with no memory afterward, and serious injuries and deaths have occurred, which is why regulators warn against use in anyone who has experienced such an episode. Next-morning impairment can also make driving dangerous even when a person feels awake. Second, combination with other depressants: taken with alcohol, opioids, benzodiazepines, or other sedatives, zolpidem compounds CNS and breathing suppression and can be dangerous or fatal. Tolerance and dependence can develop with continued use, and abrupt discontinuation can cause withdrawal, so it should be stopped under medical guidance. Any pill obtained outside a licensed pharmacy can be counterfeit and may contain other substances, including fentanyl, so naloxone (over the counter in the U.S. since 2023) is worth having on hand. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: MedlinePlus; FDA; SAMHSA
Legal status (US)
In the United States, zolpidem is a Schedule IV controlled substance under the Controlled Substances Act: it has an accepted medical use and a lower abuse potential than Schedule II or III drugs, but it still carries a recognized risk of abuse and dependence and is available only by prescription. Possessing or selling it without a valid prescription is illegal. Internationally, zolpidem is controlled under the United Nations Convention on Psychotropic Substances, with penalties varying by country. For country-by-country legal detail, see our legality pages.
Source: DEA; UN Convention on Psychotropic Substances (1971)
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With depressants, the danger is over-sedation: if someone is very drowsy, hard to wake, or breathing slowly, treat it as an emergency.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 5732PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamidePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C19H21N3OPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)CPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- ZAFYATHCZYHLPB-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- ambien, Zolpidemum, Sanval, Zolpidem civ, Edlular, Zolpi Lich, Ambien, Zolpidem (INN), zolpidem Ambien, Sanval (TN), BSPBio_002278PubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- 3 DOSAGE FORMS AND STRENGTHS Zolpidem Tartrate Tablets, USP is available in 5 mg and 10 mg strength tablets for oral administration. Tablets are not scored. ZolopenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Zolpidem is a "Z-drug" — not a benzodiazepine, though it acts selectively at the same GABA receptor — used specifically to treat insomnia. It produces rapid sedation and sleep onset with comparatively little of the anti-anxiety or muscle-relaxant effect of the benzodiazepines. Its action is short, matched to a night's sleep, and it is intended for short-term use.PubChem CID 5732 + DailyMed label ↗ · retrieved 2026-06-18
- Risks
- Zolpidem's most distinctive hazard is complex sleep behaviour: people have walked, driven, eaten, made phone calls or done other things while not fully awake and with no memory of it afterward — behaviours that have caused serious injuries and deaths and that carry a boxed warning. Beyond that, it causes next-day drowsiness and impaired coordination, and — like other sedatives — combining it with opioids, alcohol or other CNS depressants adds to the danger of respiratory depression. It can produce tolerance and dependence, with rebound insomnia when it is stopped.PubChem CID 5732 + DailyMed label ↗ · retrieved 2026-06-18
- Interactions
- Zolpidem's labelling warns that taking it with other CNS depressants — alcohol, opioids and other sedatives — produces additive sedation and can dangerously deepen respiratory depression, so the doses may need lowering and the combinations avoided. It also flags that the risk of complex sleep behaviours climbs when zolpidem is combined with other CNS depressants or taken above the recommended amount, and notes interactions with drugs that affect the CYP3A4 enzyme.DailyMed §7 / boxed warning ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 149different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 149 variants
- Strength
- ZOLPIDEM TARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Advanced Rx of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0087 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 6.25 mg/1
- Imprint
- A
- Color
- pink
- Shape
- ROUND
- Form
- TABLET, COATED
- Labeler
- Cosette Pharmaceuticals, Inc.
- Schedule
- CIV
- NDC
- 0713-5501 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 6.25 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 63629-4708 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 12.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Proficient Rx LP
- Schedule
- CIV
- NDC
- 71205-286 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Advanced Rx Pharmacy of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0322 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Advanced Rx of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0061 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- REMEDYREPACK INC.
- Schedule
- CIV
- NDC
- 70518-3943 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 12.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, COATED
- Labeler
- Sanofi-Aventis U.S. LLC
- Schedule
- CIV
- NDC
- 0024-5521 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 6.25 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Asclemed USA, Inc.
- Schedule
- CIV
- NDC
- 76420-318 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 12.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Asclemed USA, Inc.
- Schedule
- CIV
- NDC
- 76420-319 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Advanced Rx of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0059 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, COATED
- Labeler
- Advanced Rx of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0060 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CIV
- NDC
- 51407-941 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Torrent Pharmaceuticals Limited
- Schedule
- CIV
- NDC
- 13668-007 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CIV
- NDC
- 51407-942 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Torrent Pharmaceuticals Limited
- Schedule
- CIV
- NDC
- 13668-008 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Cosette Pharmaceuticals, Inc.
- Schedule
- CIV
- NDC
- 0713-5401 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- NorthStar Rx LLC
- Schedule
- CIV
- NDC
- 16714-621 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ACI Healthcare USA, Inc
- Schedule
- CIV
- NDC
- 71093-155 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- NorthStar Rx LLC
- Schedule
- CIV
- NDC
- 16714-622 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- PD-Rx Pharmaceuticals, Inc.
- Schedule
- CIV
- NDC
- 72789-390 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ACI Healthcare USA, Inc
- Schedule
- CIV
- NDC
- 71093-156 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 71335-2303 ↗ · 2026-06-18
- Strength
- ZOLPIDEM TARTRATE 6.25 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Breckenridge Pharmaceutical, Inc.
- Schedule
- CIV
- NDC
- 51991-981 ↗ · 2026-06-18
Dosage
Pending medical reviewer
